MaxCyte, Inc. Payments to Acquire Investments
MaxCyte, Inc. (MXCT) reported Payments to Acquire Investments of $36.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-13
- MaxCyte, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $11.37M, a 60.62% decline year-over-year.
- MaxCyte, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $25.12M, a 27.49% decline year-over-year.
- MaxCyte, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $28.25M, a 13.11% decline year-over-year.
- MaxCyte, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $34.51M, a 11.49% decline year-over-year.
- MaxCyte, Inc. payments to acquire investments for fiscal 2025 was $126.29M, a 16.29% decline from fiscal 2024.
- MaxCyte, Inc. payments to acquire investments for fiscal 2024 was $150.86M, a 40.86% decline from fiscal 2023.
- MaxCyte, Inc. payments to acquire investments for fiscal 2023 was $255.09M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 9 month as first filed | Payments to Acquire Investments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $11.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $36.49M 10-Q · filed 2026-08-13 | $64.75M derived: sum of 3 quarters · filed 2026-08-13 | $99.26M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $25.12M 10-Q · filed 2026-05-13 | $53.38M derived: sum of 2 quarters · filed 2026-05-13 | $87.89M derived: sum of 3 quarters · filed 2026-05-13 | $116.76M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $28.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $62.76M derived: sum of 2 quarters · filed 2026-03-25 | $91.64M derived: sum of 3 quarters · filed 2026-08-13 | $126.29M 10-K · filed 2026-03-25 | |
| 2025-09-30 | $34.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $63.39M derived: sum of 2 quarters · filed 2026-08-13 | $98.03M 10-Q · filed 2025-11-13 | $130.55M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $28.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $63.52M 10-Q · filed 2026-08-13 | $96.04M derived: sum of 3 quarters · filed 2026-08-13 | $135.03M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $34.65M 10-Q · filed 2026-05-13 | $67.16M derived: sum of 2 quarters · filed 2026-05-13 | $106.15M derived: sum of 3 quarters · filed 2026-05-13 | $137.46M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $32.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $71.50M derived: sum of 2 quarters · filed 2026-03-25 | $102.81M derived: sum of 3 quarters · filed 2026-03-25 | $150.86M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $38.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $70.30M derived: sum of 2 quarters · filed 2025-11-13 | $118.34M 10-Q · filed 2025-11-13 | $187.81M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $31.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $79.35M 10-Q · filed 2025-08-06 | $148.83M derived: sum of 3 quarters · filed 2025-08-06 | $229.49M derived: sum of 4 quarters · filed 2025-08-06 | |
| 2024-03-31 | $48.04M 10-Q · filed 2025-05-08 | $117.52M derived: sum of 2 quarters · filed 2025-05-08 | $198.18M derived: sum of 3 quarters · filed 2025-05-08 | $245.32M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $69.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $150.14M derived: sum of 2 quarters · filed 2025-03-11 | $197.28M derived: sum of 3 quarters · filed 2025-03-11 | $255.09M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $80.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $127.81M derived: sum of 2 quarters · filed 2024-11-06 | $185.62M 10-Q · filed 2024-11-06 | $185.62M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $47.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $104.95M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $57.81M 10-Q · filed 2024-05-07 | ||||
| 2022-09-30 | $213.54M 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |